PepGen Inc. Common Stock (PEPG)
PepGen Inc. (PEPG) is a biotechnology company focused on the development of innovative gene delivery therapies for neurological and rare diseases. Utilizing proprietary proprietary peptide engineering and delivery platform technologies, PepGen aims to enhance the delivery and efficacy of oligonucleotide therapies to target tissues, including the central nervous system. The company's approach seeks to address limitations of existing treatments and expand therapeutic options for underserved patient populations.
Company News
U.S. stocks traded lower midday, with the S&P 500 dropping 1%. Accenture reported strong Q4 earnings, beating analyst estimates, while several other companies experienced significant stock price movements.
A class action lawsuit has been filed against PepGen alleging false and misleading statements about the company's drug PGN-EDO51, its CONNECT2 study effectiveness, and clinical prospects during the period of March 7, 2024 to March 3, 2025.
Biotechnology company PepGen reported Q2 2025 earnings with a narrower net loss of $(0.70) per share, better than analyst expectations. The company continues developing oligonucleotide therapies for neuromuscular diseases and expects to share clinical trial data in Q4 2025 and Q1 2026.
TXO, PEPG and ERO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 25, 2024.